FGF-21

FGF-21

FGF-21 詳細

Molecule Name
Fibroblast growth factor 21
分子の別称
FGF-21, FGF21
Drug Development Progress
治験薬の数10
市販薬剤の数0
研究&開発段階Phase 3 Clinical
ターゲットの別称
FGF21
バックグランド
Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.

FGF-21 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
PegozaferminBIO89-100; TEV-47948Phase 3 ClinicalTeva Pharmaceutical Industries Ltd
Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
詳細
Efimosfermin alfaLLF-580; BOS-580; GSK-6519754Phase 3 ClinicalNovartis Pharma Ag
Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
詳細
EfruxiferminAKR-001; AMG-876; EFX; Fc-FGF21(RGE)Phase 3 ClinicalAmgen Inc
Diabetes Mellitus; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
詳細
MWN-105MWN-105Phase 2 ClinicalShanghai Minwei Biotechnology Co Ltd
Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight
詳細
TQA-2225AP-025; TQA2225; TQA-2225Phase 2 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
詳細
HEC-88473HEC-88473; HEC88473; APL-18881Phase 2 ClinicalDongguan Hec Taigen Biopharmaceuticals Co Ltd
Diabetes Mellitus, Type 2; Hepatitis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
詳細
B-1344B-1344Phase 1 ClinicalTasly Biomedical Co Ltd
Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease
詳細
DMR-2301DMR-2301; DMR2301Phase 1 ClinicalShanghai Duomirui Biotechnology Co Ltd
Metabolic Dysfunction-Associated Steatotic Liver Disease
詳細
ZT-003ZT003; ZT-003Phase 1 ClinicalBeijing QL Biopharmaceutical Co Ltd
Diabetes Mellitus; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
詳細
AP-026TQA2226; AP026; AP-026; TQA-2226Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight
詳細